Business Context and Reporting Period
This Form 8-K was filed by Intrexon Corporation (not Precigen, Inc.) on November 20, 2018. The report details a corporate transaction involving the acquisition of Intrexon T1D Partners, LLC by ActoBio Therapeutics, Inc., a wholly-owned subsidiary of Intrexon.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity issuance event.
Material Changes
- Equity Issuance: Intrexon issued an aggregate of 1,933,737 shares of common stock (no par value) on November 20, 2018.
- Transaction Purpose: The shares were issued in connection with the acquisition of Intrexon T1D Partners, LLC.
- Insider Participation: Entities affiliated with Randal J. Kirk, the Chairman and CEO, acquired 396,668 of the issued shares.
- Regulatory Status: The shares were issued in a private placement to accredited investors under Section 4(a)(2) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, or specific risk factors related to the company's operations. It strictly reports the unregistered sale of equity securities.
Investor Verification Checklist
- Verify the total number of shares issued (1,933,737) and the portion acquired by CEO-affiliated entities (396,668).
- Confirm the legal structure of the acquisition involving ActoBio Therapeutics, Inc. and Intrexon T1D Partners, LLC.
- Review the impact of this private placement on the company's total outstanding share count and potential dilution.
- Note that the registrant name in the filing is Intrexon Corporation, not Precigen, Inc.